Skip to main content

Table 5 Accuracy of the GEP test and sentinel lymph node status

From: Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients

 

GEP Class

SLN status

% (95% CI)

% (95% CI)

RFS

 Sensitivity

70% (62–78%)

66% (57–74%)

 Specificity

71% (67–76%)

65% (58–71%)

 PPV

48% (41–55%)

52% (44–60%)

 NPV

87% (82–90%)

76% (69–82%)

DMFS

 Sensitivity

75% (66–83%)

67% (57–76%)

 Specificity

69% (65–74%)

62% (55–68%)

 PPV

40% (33–47%)

42% (34–50%)

 NPV

91% (87–94%)

82% (76–88%)

MSS

 Sensitivity

85% (72–94%)

79% (63–90%)

 Specificity

64% (60–69%)

58% (52–64%)

 PPV

19% (14–25%)

21% (15–28%)

 NPV

98% (95–99%)

95% (91–98%)

  1. CI confidence interval, DMFS distant metastasis-free survival, GEP gene expression profile, MSS melanoma-specific survival, NPV negative predictive value, PPV positive predictive value, RFS recurrence-free survival, SLN sentinel lymph node